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08 The Journal of Thoracic and Cardiobjective: With increased life expectancy and improved technology, valve replace-
ent is being offered to increasing numbers of elderly patients with satisfactory
linical results. By using standard econometric techniques, we estimated the relative
ost-effectiveness of aortic valve replacement by drawing on a large prospective
atabase at our institution. By using aortic valve replacement as an example, this
ntroductory report paves the way to more definitive studies of these issues in the
uture.
ethods: From 1961 to 2003, 4617 adult patients underwent aortic valve replace-
ent at our service. These patients were provided with a prospective lifetime
ollow-up. As of 2005, these patients had accumulated 31,671 patient-years of
ollow-up (maximum 41 years) and had returned 22,396 yearly questionnaires. A
tatistical model was used to estimate the future life years of patients who are currently
live. In the absence of direct estimates of utility, quality-adjusted life years were
stimated from New York Heart Association class. The cost-effectiveness ratio was
alculated by the patient’s age at surgery.
esults: The overall cost-effectiveness ratio was approximately $13,528 per quality-
djusted life year gained. The cost-effectiveness ratio increased according to age at
urgery, up to $19,826 per quality-adjusted life year for octogenarians and $27,182
er quality-adjusted life year for nonagenarians.
onclusions: Given the limited scope of this introductory study, aortic valve
eplacement is cost-effective for all age groups and is very cost-effective for all but
he most elderly according to standard econometric rules of thumb.
 
he first successful heart valve replacement was performed in 1960.1 Cur-
rently, approximately 75,000 heart valve replacements are performed per
year in the United States. Heart valve replacement has long been proven to
e clinically effective in extending life expectancy and improving quality of life. It
s increasingly performed in older patients, including those aged more than 80 years
r even more than 90 years. At our institution, the mean age of patients undergoing
ortic valve replacement (AVR) increased from 47 years to 69 years during the past
 decades (Figure 1). The clinical effectiveness of this technique has been well
ocumented, but the cost-effectiveness, to our knowledge, has not. Because this
ntroductory study is the first venture into this new area, we used standard econo-
etric techniques to estimate the relative cost-effectiveness of AVR, especially for
he elderly.
aterials and Methods
rom 1961 to 2003, 4617 patients aged 20 years or more underwent AVR at 3 hospitals in
ortland, Oregon. Thirty-four percent of the patients had concomitant coronary artery bypass
rafting, and none of the patients had other concomitant valve-replacement surgeries. Forty-
even percent of patients underwent AVR for aortic stenosis, 14% for aortic insufficiency, and
vascular Surgery ● March 2007
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TS9% for both aortic stenosis and insufficiency. The mean age at
urgery was 65 years (range 20-94 years), 502 patients (10.9%)
ere octogenarians, and 23 patients (0.5%) were nonagenarians
Figure 2).
Beginning with the first patient who underwent valve replace-
ent, a prospective lifetime follow-up service was implemented.
ll patients undergoing valve replacement are followed up at
nnual intervals using a combination of mailed questionnaires and
elephone interviews. The yearly surveys include questions regard-
ng complications and medications. They also include questions
egarding angina, shortness of breath, and daily activity for ascer-
ainment of the New York Heart Association functional class
NYHA). As of the end of 2005, these patients had accumulated
1,671 follow-up years with a maximum of 41 years and had
eturned 22,396 yearly questionnaires.
Among the 4617 patients who underwent AVR, 2382 were
ocumented as dead, and the other 2235 were still being followed
t the time of the study (statistically, these patients are termed
censored”). To estimate the complete lifetimes of patients who
ave not yet died, a time of death was simulated using a Gompertz
arametric regression model. Gompertz regression has been
idely used to model survival time in survival analysis, especially
or elderly persons.2 The model was developed using data from all
atients who underwent heart valve replacement, and the predic-
ors included age, gender, valve implant position, and concomitant
oronary artery bypass grafting.
Abbreviations and Acronyms
AVR  aortic valve replacement
CER  cost-effectiveness ratio
NYHA New York Heart Association
QALY  quality-adjusted life year
igure 1. Mean age of patients who underwent AVR by surgery
ear. AVR, aortic valve replacement.
The Journal of Thoracicost-effectiveness Ratio: Net Cost of Additional
uality-adjusted Life Years
he cost-effectiveness of AVR was assessed by comparing
he surgical results with the natural history of patients with
noperated heart disease who would have been surgical
andidates. The cost-effectiveness ratio (CER) was calcu-
ated for each age at surgery as CER  (A-B)/(C-D) (de-
ned below), and the results were presented by grouping
-year age intervals.
A. The lifetime costs of heart valve replacement
B. The lifetime costs of maintaining patients with un-
operated heart valve disease
C. The quality-adjusted life years (QALYs) experienced
after heart valve replacement
D. The QALYs experienced by patients with unoperated
heart valve disease
A. The lifetime costs of AVR consist of 3 major
components: (1) the cost of the original surgery; (2)
the costs of ongoing maintenance (physician visits,
echocardiograms, and anticoagulation therapy); and
(3) the costs of treating valve-related complications
(thromboembolism, bleeding, endocarditis, perival-
vular leak, valve thrombosis, valve explant, and re-
implantation). The cost of AVR surgery was approx-
imately $60,000 on average in 2005 at our service,
and the cost of reoperation was set to be the same as
the original surgery. Other numbers were extracted
from the literature3 and converted to 2005 dollars
using yearly inflation factors obtained from the con-
sumer price index, which is complied by the Bureau
of Labor Statistics (http://inflationdata.com/Infla-
igure 2. Number of patients who underwent AVR by age at
urgery. AVR, aortic valve replacement.tion/Inflation_Rate/HistoricalInflation.aspx). For pa-
and Cardiovascular Surgery ● Volume 133, Number 3 609
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TStients who are currently alive, future life years were
simulated using the Gompertz statistical model. To
project the cost during these simulated future life
years, physician visits and echocardiograms were
assumed to occur annually; valve-related events
rates were assumed to occur at the same constant
rates as during the observed patient-years.
B. The costs of maintaining patients with unoperated
heart valve disease was set at zero, because the
numbers were difficult to obtain or estimate. Note
that this has the effect of overestimating the CER.
C. The QALYs were estimated by mapping quality-of-
life scores to NYHA functional class. Life years spent
in NYHA classes I, II, III, and IV were estimated to
be equivalent to 0.85, 0.71, 0.57, and 0.43 QALYs,
respectively.4 NYHA classes during follow-up were
assessed by follow-up questionnaires regarding angina,
shortness of breath, and daily activity. Follow-up
questionnaires were usually obtained annually, but
when not available for a certain year, the information
was generated by linear interpolation from available
years. For future simulated life years, NYHA classes
were linearly interpolated between the latest avail-
able NYHA classes and class IV (assumed for the
end of life).
D. The life years of patients with unoperated heart valve
disease were estimated using a systematic review of
the English language literature concerning the natu-
ral history of heart valve disease in the aortic posi-
tion. The literature search was performed using Med-
line, the American College of Cardiology/America
Heart Association guidelines for the management of
patients with valvular heart disease,5 and an article
by Kloster and Morris6 containing key references of
the natural history of valvular heart disease. The
study inclusion criteria were as follows: (1) The
Kaplan–Meier curve(s) was/were given; (2) the sam-
ple size was given; (3) the patients had severe dis-
ease or were operative candidates who did not get
surgery. When several articles were reported for the
same group of patients, only the most recent article
was used. The survival curves from the selected
series were duplicated by digitizing the original
curves in the article. Then, an average curve was
computed, weighted by sample sizes, and the mean
survival time was calculated by measuring the area
under this average curve. For each individual patient,
a lifetime was assigned by randomly sampling the
survival time on the weighted average survival
curves based on the probability of survival. QALYs
for patients with unoperated heart valve disease were
linearly interpolated between preoperative NYHA class
and class IV. If preoperative NYHA class was not s
10 The Journal of Thoracic and Cardiovascular Surgery ● Marcavailable, it was randomly sampled on the basis of the
probability of known preoperative NYHA class.
The simulation was repeated 100 times. The numbers in
he “Results” section were based on 1 simulation, and the
5% ranges were added to the CERs. The study was ap-
roved by the institutional review board.
esults
urvival (mean  standard error) after AVR was 50% 
.9%, 20%  1.0%, 6.8%  0.8%, and 3.9%  0.8% at 10,
0, 30, and 40 years, respectively (Figure 3). For the 2382
atients who died, a total of 17,525 follow-up years were
bserved. For the 2235 censored patients, a total of 14,146
ollow-up years were documented, and an additional 21,652
95% range was 21,090-22,401) years were imputed using
he Gompertz regression model. The mean survival years
ere 12.4 (9.4 QALYs) for AVR, and the majority of the
ifetimes were in NYHA classes I and II (Figure 4, A).
The literature search found 126 studies on unoperated
ortic heart valve disease that were published between 1951
nd 2004. Five series of aortic stenosis7-9 that matched the
nclusion and exclusion criteria were used to compose the
eighted average curve (Figure 3), and 2 studies for aortic
egurgitation were not included because of the small sample
ize and short follow-up times. The mean survival time was
.2 years (1.2 QALYs) for aortic valve disease, and the
ajority of the life years were in NYHA class IV (Figure 4, B).
The total life years after AVR were 53,323, which was
quivalent to 39,505 QALYs (total area of the dark gray
ars in Figure 5, A). The total expected life years without
igure 3. Survival of patients with severe, unoperated aortic
alve disease from the literature7-9 (the thin light gray curves are
eries from literature, and the thick light gray curve is the
eighted average) and survival of 4617 patients after AVR from
he authors’ series (thick black curve).urgery were 10,157, which was equivalent to 6159 QALYs
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TSarea of the dark gray bars in Figure 5, B). The total QALYs
ained by heart valve replacement was the difference, or
3,346 QALYs, shown by the patient’s age at surgery inl
igure 6, A. The average QALYs gained (Figure 6, B) was
omputed by dividing the bars in Figure 6, A by those in
igure 2, the number of patients at each surgical age.
The total lifetime cost of AVR was $451 million in 2005
ollars (Figure 7, A): $277 million for the original surgery;
50 million for ongoing maintenance; and $124 million for
reating valve-related events. The average cost per life year
Figure 7, B) is computed by dividing the bars in Figure 7,
 by those in Figure 2. The CER by age at surgery was
alculated by dividing the lifetime costs at each age group
Figure 7, A) by the lifetime QALYs gained at that age
roup (Figure 6, A), and is shown in Figure 8. The overall
ER was $13,528 per QALY and increased with age, up to
19,826 per QALY for octogenarians and $27,182 per
ALY for nonagenarians.
iscussion
ost-effective analysis has long been used to compare 2
reatments on the basis of their economic and clinical out-
omes. The results of a cost-effective analysis are summa-
ized as a CER, of which the numerator is the difference of
he costs of the 2 treatments and the denominator is the
igure 4. A, Observed survival after AVR (black curve in Figure 3)
y follow-up NYHA class. The areas of the different shadings are
roportional to the patients’ NYHA status during the follow-up
ears. For example, the majority of patients lived with NYHA
lass I or II during their remaining lifetime (big areas of light gray
olors). B, Estimated survival (thick gray line in Figure 3) by
ollow-up NYHA class as if patients in (A) did not undergo operation.
he majority of patients would have lived with NYHA class IV
uring their remaining lifetime (big area of black color). AVR,
ortic valve replacement; NYHA, New York Heart Association.ifference of the QALYs. Thus, the CER provides the cost v
The Journal of Thoracicigure 5. A, Total life years (light gray bars) and respective
ALYs (dark gray bars) after AVR by age at surgery. This shows
pproximately 75% diminution from perfect health across all age
roups after AVR. B, Total life years (light gray bars) and respec-
ive QALYs (dark gray bars that are superimposed on the light
ray bars) for natural history by age at surgery. This shows
pproximately 60% diminution from perfect health across all age
roups. AVR, Aortic valve replacement; QALY, quality-adjusted
ife year.igure 6. A, Total QALYs gained after AVR by age at surgery. The
eight of each bar equals the difference of height of the dark gray
ars in Figure 5, A and B. B, Mean QALYs gained after AVR by age
t surgery (total QALYs gained in Figure 5, A divided by total
umber of patients in Figure 2 at each age group). AVR, aortic
alve replacement; QALY, Quality-adjusted life year.
and Cardiovascular Surgery ● Volume 133, Number 3 611
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TSor gaining 1 additional QALY and is commonly used to
udge whether a treatment is worth its costs compared with
n alternative treatment. For example, the addition of driv-
r’s side air bags to safety belts results in net health benefits
t an incremental cost of $24,000 per QALY saved.10 Cor-
nary artery bypass grafting was found to be more cost-
ffective than stenting in patients with multivessel dis-
ase.11 Established since the early 1960s, AVR has become
he standard practice for severe aortic valve disease. This
tudy analyzes the cost-effectiveness of AVR compared
ith unoperated aortic valve disease. Just as for measuring
linical outcomes, the measurement of economic outcomes
n long-term studies faces the challenge of treating censored
bservations. That is, many patients (sometime the major-
ty) are still alive, and the complete life years are unknown
t the time the study is conducted. A statistical model was
sed to simulate the remaining life years and valve-related
omplications during the remaining life years. The eco-
omic end points were calculated accordingly.
According to our review of the literature and the analysis
f our own data, AVR increased the longevity and improved
he quality of life of operative candidates. However, the
perative and long-term survival are worse in older patients,
nd advanced age is known to be an independent risk factor
or both operative mortality and long-term survival. The
rimary goal of AVR in very old patients is to improve their
igure 7. A, Total lifetime costs of AVR by age at surgery. B,
ean lifetime costs of AVR by age at surgery (total cost in
igure 7, A divided by total number of patients in Figure 2 at each
ge group). The mean cost was further broken down into cost of
1) original implantation; (2) ongoing maintenance (physician
isit, echocardiogram, and anticoagulation treatment); and (3)
reatment of prosthesis valve-related events (thromboembolism,
leeding, endocarditis, perivalvular leak, valve thrombosis, and
eoperation). AVR, aortic valve replacement.uality of life. Thus, the selection of the most elderly for c
12 The Journal of Thoracic and Cardiovascular Surgery ● MarcVR is usually conservative considering the balance be-
ween risk and benefit. In addition to clinical outcomes,
conomic end points also affect clinical decision-making,
specially in the very elderly.12 The current study assessed
he life years and QALYs gained after AVR and the cost-
ffectiveness in all ages. Compared with 2.2 years of ex-
ected lifetime and 1.2 QALYs with nonsurgical treatment,
VR has extended the mean survival to 12.4 years and 9.4
ALYs. Even for the octogenarians and nonagenarians, the
ean survival after AVR was 7.2 years (5.5 QALYs) and
.8 years (3.9 QALYs), respectively.
The natural history of heart valve disease was derived
rom older studies, and only a small proportion of the
atients in those studies, either surgical candidates or those
ith advanced disease, were included. Fourteen percent of
he study patients had aortic insufficiency, but none of the
iterature regarding natural history of aortic insufficiency
as used because of the small sample sizes and short
ollow-ups. Because of the small sample sizes and limited
nformation in these studies, the mean survival time is not
stimated accurately, and it cannot be adjusted for age,
ender, or other factors. Medical treatment also has im-
roved since most of these studies were published, and the
ife expectancy of patients with severe heart valve disease
hould be greater than described in the historical literature
sed for this report. This might lead to an overestimation of
ost-effectiveness (lower CER). On the other hand, we
igure 8. Average CER (cost per QALY) by age at surgery. Error
ars indicate 95% ranges from 100 simulation. CER less than
20,000/QALY was judged as very cost-effective, between $20,000/
ALY to $100,000/QALY as acceptable, and more than $100,000 as
ot cost-effective.13,14 The CERs were less than $20,000/QALY for
ost of the age groups. It was higher for older patients (>80
ears), but still less than $100,000/QALY. CER, Cost-effectiveness
atio; QALY, quality-adjusted life year.ounted the lifetime cost of AVR but did not subtract the
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TSosts of caring for patients with severe, unoperated heart
alve disease. This resulted in an underestimation of cost-
ffectiveness (higher CER).
There are several standardized tools widely used to mea-
ure quality of life, such as the short form health surveys [36
tems and 12 items], EuroQol-5D, Quality of Well-Being
cale, Health Utilities Index, and Health and Activities
imitations Index. The current study included patients from
961 to 2003, and data for standard quality of life are not
vailable for patients who underwent operation in the earlier
ays. Thus, the QALYs were estimated by mapping quality
f life scores to NYHA functional class. NYHA is not a
erfect measure of quality of life, but it has been demon-
trated to reflect, or correlate with, quality of life in the
iterature.4
It would be ideal if we could give a precise, personalized
stimate of the lifetime cost of AVR. We used the risk
odel to estimate the lifetime adjusted by patient charac-
eristics; we estimated the number of valve-related compli-
ations and the cost of treating those complications. To
roject the cost during these simulated future life years,
alve-related event rates were assumed to occur at the same
onstant rates as during the observed patient-years. For
ome valve-related events (eg, structural valvular deteriora-
ion), the event rate is not constant and different for me-
hanical and biological valves. However, constant rates
ere used for this introductory study. For the cost of hos-
italization, we used a flat average number of $60,000 for
very patient regardless of age, comorbidities, length of
tay, and surgical era.
The lifetime cost of AVR decreased with increasing age
Figure 7, B) (older patients have shorter lifetimes to main-
ain and to experience valve-related complications), but
ot as fast as the remaining QALYs (Figure 6, B). Thus,
he CER increased according to age at surgery (Figure 8).
till, the CER was less than $20,000 per QALY for all but
he nonagenarians, and it was only $27,182 per QALY for
hem. There are generally accepted thresholds: A treatment
osting less than $20,000/QALY is considered very cost-
ffective, between $20,000 and $100,000/QALY is accept-
ble, and more than $100,000/QALY is not cost-effectiv e . 13,14
espite the limitations, this is well within generally ac-
epted thresholds, making AVR very cost-effective.
This article was our first foray into this new area of
conometric research, and we have provided an overview
sing AVR as the test dataset. Part of the value is to
ntroduce the cardiac surgical community to this type of
The Journal of Thoracicnalysis. Our next step of investigation will be gathering
etailed data and refining analysis methodology to provide
ore specific and practical results for definitive studies.
onclusions
VR was shown to be cost-effective based on generally
ccepted thresholds for CER, even for the very elderly.
owever, these thresholds are arbitrary. An econometric
ethod of further quantifying the values of these QALYS,
r rather the life years that they are derived from, has
volved and been used to show that these thresholds are
ctually conservative.15
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